DMD and myocarditis: Although not observed in this clinical trial, three cases of transient myositis (two of which were associated with myocardial inflammation) were observed roughly 4 weeks after infusion of fordadistrogene movaparvovec; similar manifestations have been associated with other miniaturized dystrophin gene therapy candidates and are related to a T cell-mediated response against the hinge 1 or spectrin repeat 1 protein domains of dystrophin25.